Insulet’s (PODD) robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on the significant growth opportunities in the Type 2 diabetes space. PODD carries a Zacks Rank #2 (Buy) currently.Factors Driving PODD StockInsulet is making significant strides in its key strategic imperatives to help patients manage diabetes efficiently.  The company’s first strategy revolves around increasing access and awareness of Omnipod products. In the second quarter of 2024, ...